Abstract-Evidence indicates that Ang II (angiotensin II) activates STAT3 (signal transducer and activator of transcription 3) in cardiomyocytes. However, the mechanisms underlying STAT3 activation and downstream responses are not fully known. In this study, we show that Ang II caused biphasic STAT3 activation in cardiomyocytes. A rapid and early activation was mediated by direct association between TLR4 (toll-like receptor-4) and STAT3. This early activation increased IL-6 (interleukin-6) production, which in turn, induced the second STAT3 activation through the IL-6/gp130 (glycoprotein 130)/JAK2 (Janus-family tyrosine kinases 2) pathway, resulting in unregulated expression of genes for cardiac remodeling. Moreover, STAT3 inhibition or TLR4 knockout in mice protected against Ang II-induced hypertrophy, fibrosis, and cardiac functional deficits. Thus, Ang II-induced STAT3 activation in cardiomyocytes was biphasic, providing a sequential induction of IL-6 and myocardial remodeling genes, respectively. This work supports a novel mechanism on STAT3 activation in Ang II-induced cardiac dysfunction and remodeling. (Hypertension.
H ypertensive cardiac remodeling is characterized by left ventricular hypertrophy and interstitial fibrosis, leading to heart failure. 1 Clinical and experimental studies report that deregulated Ang II (angiotensin II), the major effector in the renin-angiotensin system, plays a role in ventricular remodeling. 2 Ang II induces an inflammatory cardiomyocyte phenotype, 3 cellular hypertrophy, 4 and increased extracellular matrix deposition. 5 Ang II differentially activates STAT (signal transducer and activator of transcription) proteins, contributing to cardiac dysfunction and heart failure. 6 However, the signaling mechanisms by which Ang II specifically activate STAT proteins in myocardial injury are unclear.
STATs are activated by nonreceptor JAK (Janus-family tyrosine kinases), a family of 4 members, of which Tyk2, JAK1, and JAK2 are expressed in cardiomyocytes. 7 Additionally, all 7 STATs are expressed in the heart, 7 which are recruited to activating receptors and tyrosine-phosphorylated by JAK. The phosphorylated STATs dissociate from the receptors, dimerize, and translocate to the nucleus to target genes. STATs regulate transcription of genes involved in inflammation, cellular signaling, apoptosis, and extracellular matrix deposition. 8 STAT3 plays a pivotal role in ventricular remodeling. 9, 10 Ang II can induce rapid phosphorylation of STAT1 and STAT2
with delayed phosphorylation of STAT3 in cardiomyocytes, 11 the latter possibly attributed to an initial synthesis and release of IL-6 (interleukin-6), 11, 12 which then binds the IL-6 receptor subunit gp130 (glycoprotein 130), activating STAT3 for target gene expression. 13 However, studies have also reported rapid activation of STAT3 in cardiomyocytes, 14 underscoring the importance of further studies to elucidate the mechanisms of STAT3 activation by Ang II.
One novel mechanism of STAT activation may be through TLR4 (toll-like receptor 4). TLR4 is a pattern recognition receptor in innate immunity, 15 which is implicated in Ang IIinduced cardiac remodeling. 16 Importantly, we found that Ang II binds to a TLR4 co-receptor in mediating cardiac inflammation. 3 In other diseases, Ang II engages TLR4 to activate STAT3 in abdominal aortic aneurysms in mice. 17 These studies raise the interesting possibility that Ang II may activate STAT3 in cardiomyocytes through TLR4. We tested the hypothesis that Ang II-induced cardiac remodeling is regulated by STAT3 activation that is dependent on TLR4. The hypothesis was tested in Ang II-administered mouse models or cardiomyocytes with blockade of TLR4 or STAT3. Results indicated that Ang II stimulated direct binding of STAT3 with TLR4, resulting in STAT3 activation. Blockade of either TLR4 or
Methods
The techniques and data that support the results of this study are available from the corresponding author on reasonable request.
Cell Culture and Reagents
H9C2 rat cardiomyoblast line was obtained from the Shanghai Institute of Biochemistry and Cell Biology (Shanghai, China). H9C2 cells exhibit identical responses as primary cardiomyocytes, especially in response to Ang II. 18 Cells were cultured in DMEM (Gibco, Eggenstein, Germany) containing 4500 mg/L d-glucose, supplemented with 10% fetal bovine serum (Hyclone, Logan, UT), 100 U/ mL penicillin, and 100 U/mL streptomycin.
Ang II was purchased from Aladdin (Shanghai, China). Cellpermeable STAT3 inhibitor S3i-201, TLR4 inhibitor TAK-242, and gp130 inhibitor SC144 were purchased from Selleck Chemicals (Huston, TX). S3i-201 was dissolved in dimethyl sulfoxide. Effective concentration of S3i-201 was based on previous study showing inhibition of STAT3 in breast cancer cells.
19 DMSO solution (1‰) was vehicle control. Primary antibodies (used at 1:300 dilution) against TLR4 (sc-30002), MyD88 (sc-74532), JAK2 (sc-390539), Col-1 (Collagen 1; sc-25974), TGF-β (transforming growth factor-β; sc-146), MyHC (myosin heavy chain; sc-376157), Lamin B (sc-6216), GAPDH (sc-32233), and secondary antibodies (used at 1:2000 dilution; anti-mouse IG-HRP [sc-3744]; anti-rabbit IG-HRP [sc2313])were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Primary antibodies against p-STAT3-705 (9145s) and STAT3 (12640S) were purchased from Cell Signaling Technology (Danvers, MA) and used at 1:1000 dilution. Rhodamine phalloidin was purchased from Enzo Life Sciences (Ann Arbor, MI).
Ang II-Induced Cardiac Remodeling
Cardiac hypertrophy was induced in mice through Ang II challenge. Twenty-four male wild-type (WT) C57BL/6J (stock No 000664) and 12 TLR4
−/− mice 20 (B6.B10ScN-Tlr4 lps-del /JthJ; Stock No 007227) were used for study (Jackson Laboratory, Bar Harbor, ME). This TLR4 −/− harbors a 74 723 bp deletion that completely removes the TLR4 coding sequence. Mice were housed with a 12:12 h light-dark cycle at constant room temperature, fed standard rodent diet, and acclimated to the laboratory for at least 1 week before initiating studies. All animal care and experimental procedures were in accordance with directives in the Guidelines for the Care and Use of Laboratory Animals (US National Institutes of Health). Animal care and experimental protocols were approved by the Committee on Animal Care of Wenzhou Medical University.
Mice were randomly divided into 5 weight-matched groups: (1) nontreated WT (control, n=6), (2) nontreated TLR4 −/− (KOTLR4, n=6), (3) WT challenged with Ang II (Ang II, n=7), (4) TLR4 −/− challenged with Ang II (Ang II+KOTLR4, n=6); and (5) WT challenged with Ang II and treated with STAT3 inhibitor S3i-201 (Ang II+S3i-201, n=6). Cardiac remodeling was induced in mice by subcutaneous injections of Ang II at 1.4 mg/(kg day) for 4 weeks in pH=7.2 phosphate buffer. Control mice received same amount of buffered saline (100 μL/day) alone. STAT3 inhibitor S3i-201 was administered intraperitoneally at 5 mg kg every other day. Systolic blood pressure (SBP) was measured by noninvasive tailcuff Pressure Analysis System (BP-98A; Softron, Tokyo, Japan) 21 at indicated times.
One day before killing, Doppler analysis was performed to determine cardiac function. Mice were anesthetized using isoflurane, and echocardiography was performed by SONOS 5500 ultrasound (Philips Electronics, Amsterdam, Netherland) with a 15-MHz linear array ultrasound transducer. Four weeks after initiation of treatments, mice were killed, body weights were recorded, and blood samples were collected. Heart tissues were harvested for histology and gene and protein analyses.
Statistical Analysis
All in vitro data reported represent at least 3 independent experiments and is expressed as means±SEM. All statistical analyses were performed using GraphPad Prism 5.0 (GraphPad, San Diego, CA). Student t test or one-way ANOVA followed by multiple comparisons test with Bonferroni correction were used to analyze the differences between sets of data. P<0.05 was considered significant.
All other data are included within the article or in the online-only Data Supplement or available from the authors on request.
Results

Ang II Evokes Two Waves of STAT3 Activation, With Only the Second Wave Dependent on IL-6/ IL-6R
We established the time course of STAT3 activation in the rat H9C2 cardiomyoblast line and the primary rat cardiomyocytes. The treatment of cells with 1 µmol/L Ang II increased STAT3 Tyr705 phosphorylation, which peaked at 2 distinct waves. Ang II induced the first wave of STAT3 phosphorylation at 15 minutes, peaking at 30-60 minutes and decreasing at 120 minutes ( Figure 1A ) in H9C2 cells. The Ang II-induced second wave occurred at 12 h, with sustained phosphorylation of up to 18 h. Similar results were obtained in primary cardiomyocytes ( Figure S1A in the online-only Data Supplement). Specific tyrosine phosphorylation of STAT3 allows protein dimerization and translocation to the nucleus. 22 Therefore, we examined nuclear levels of STAT3 after Ang II exposure. As expected, nuclear p-STAT3 (Tyr705) levels paralleled the 2 waves of phosphorylation/activation at 1 and 12 h ( Figure 1B ; Figure S1B ). Immunolocalization of p-STAT3 in H9C2 cells confirmed these results ( Figure 1C) .
The biphasic nature of STAT3 activation suggested a possible paracrine mechanism in which the first STAT3 activation induced IL-6 production, which then activated the second STAT3 activation. To test this possibility, H9C2 cells were stimulated with Ang II for determination of secreted IL-6 levels. Results indicated that Ang II significantly increased secreted IL-6 levels at 12h but not earlier ( Figure 1D ), suggesting that the secreted IL-6 may in turn activate STAT3 through IL6-IL6R-gp130. 23, 24 The pretreatment of H9C2 cells with SC144, a potent inhibitor of gp130, failed to prevent Ang II-induced STAT3 phosphorylation at 1 h ( Figure 1E ) but completely prevented the Ang II activation at 12 h ( Figure 1F ). These results show that the delayed activation of STAT3 was likely mediated through the IL6R/gp130 pathway.
First Wave of Ang II-Induced STAT3 Activation Is Dependent on Direct TLR4-STAT3 Interaction
The effects of TLR4 inhibition on Ang II-mediated activation of STAT3 were determined by pretreatment of H9C2 cells with TAK-242, a cell-permeable TLR4 inhibitor that binds Cys747 of TLR4, thereby preventing recruitment of adaptor molecules. Results indicated that TAK-242 pretreatment reduced Ang II-induced STAT3 phosphorylation at both 1 and 12 h ( Figure S2A and S2B). Similar results were obtained with TLR4 knockdown (Figure S2C ), in which p-STAT3 phosphorylation was near control levels at 1 and 12 h (Figure 2A ), indicating that TLR4 was required for the Ang II-induced STAT3 phosphorylation. The results also suggested that TLR4 regulated both the early and late activation of STAT3. We investigated this possibility by silencing MyD88 in H9C2 cells ( Figure S2D ). MyD88 is an important adapter protein for NF-kB (nuclear factor-κB) activation and IL-6 production in the TLR4 signaling pathway, although TLRs may also signal without MyD88. 25, 26 Figure S2E and S2F shows that the Ang II-stimulated (12 h) increased NF-κB activity and p65 nuclear translocation were prevented with TLR4 knockdown. Silencing MyD88 reduced the Ang II-induced p-STAT3 Level at 12 h but not 1 h ( Figure 2B ), indicating a MyD88-independent mechanism of early STAT3 activation and a MyD88-dependent late activation. MyD88 knockdown also prevented about 50% of Ang II-induced (12 h) IL-6 overexpression ( Figure S2G ), indicating MyD88 signaling was partly responsible for the IL-6 production and late STAT3 activation. We further corroborated the possibility of paracrine IL-6 signaling of the late STAT3 activation by testing the condition media for its ability to activate STAT3. Condition media was collected from Ang II-stimulated H9C2 cells (12 h), which contained high levels of secreted IL-6. We found that the condition media stimulated rapid phosphorylation of STAT3 when incubated with a new batch of H9C2 cells for 1 h ( Figure 2C) . Interestingly, the condition mediainduced STAT3 phosphorylation was not affected in H9C2 cells with TLR4 knockdown, consistent with the notion that the IL-6-stimulated STAT3 activation was TLR4 independent ( Figure 2C ). Taken together, our data suggested that (1) TLR4 mediated the early Ang II-induced STAT3 activation independent of MyD88/IL6-, whereas (2) TLR4-mediated late STAT3 activation required MyD88 recruitment and IL-6.
We further investigated the MyD88/IL6-independent mechanism by which TLR4 mediated early STAT3 activation using co-immunoprecipitation. Our results show that Ang II caused rapid association between TLR4 and STAT3 ( Figure 2D ) or p-STAT3 ( Figure 2E ) in H9C2 cells and in primary cardiomyocytes ( Figure S3A ). The results also showed that JAK2 did not interact with TLR4 ( Figure 2D ), which was in contrast to a report that JAK2 is activated early in Ang II-stimulated cardiomyocytes. 11 Moreover, JAK2 knockdown using targeting siRNA ( Figure S3B ) did not alter STAT3 association with TLR4 in H9c2 cells ( Figure 2F ), further supporting our finding that TLR4-STAT3 interaction was JAK2 independent. Thus, these data suggested that Ang II induced rapid STAT3 activation through direct TLR4-STAT3 interactions, which was independent of MyD88 and IL-6/JAK2 signaling pathway.
Early STAT3 Activation Upregulates IL-6 Gene Transcription in Cardiomyocytes
We identified the target genes transcriptionally upregulated by early activated STAT3 using ChIP-PCR (chromatin immunoprecipitation-PCR) analysis. ISL-1 (insulin gene enhancer protein, factor 1) was included as positive control 27 ( Figure 3A) . Results indicated that Ang II (1 h) induced STAT3 binding to the IL-6 promoter region, consistent with the notion that early STAT3 activation induced IL-6 expression in cardiomyocytes ( Figure 3B ). With 12 h Ang II stimulation, activated STAT3 bound only to promoter regions of myocardial remodeling genes, that is, MyHC, Col-1, and TGF-β ( Figure 3C through 3E) . Moreover, the knock down of STAT3 in H9C2 cells reduced 50% of the Ang II-stimulated IL-6 ( Figure 3F ). This result is consistent with the finding that MyD88 knockdown also inhibited 50% of Ang II-stimulated IL-6 overexpression ( Figure S2G ). Thus, early STAT3 activation and MyD88/NF-κB pathway regulated IL-6 expression independently. These data provided evidence of differential gene regulation by the Ang II-induced biphasic early and late STAT3 activations, respectively, inducing transcription of IL-6 and tissue remodeling genes. The upregulated IL-6 by early STAT3 activation is predicted to further amplify STAT3 activation as positive feedback.
Late STAT3 Activation Mediates Ang II-Induced Tissue Remodeling Genes
We observed that Ang II-activated late STAT3 which bound to promoters of tissue remodeling genes. We further examined the role of STAT3 in induction of these genes in H9C2 cells with STAT3 knockdown ( Figure 4A ). Our results show that STAT3 knockdown prevented expression of Ang II-induced MyHC, Col-1, and TGF-β proteins ( Figure 4B and 4C) and mRNA ( Figure 4D) . Furthermore, pretreatment of H9C2 cells or primary cardiomyocytes with the selective STAT3 inhibitor, S3i-201, which prevents STAT3 phosphorylation and STAT3-DNA binding, 19, 28 decreased protein levels of MyHC, Col-1, and TGF-β ( Figure S4A through S4C) . The assessment of cardiomyocyte cell size indicated that S3i-201 pretreatment also prevented Ang II-induced cellular hypertrophy ( Figure 4E and 4F) . These findings show that late STAT3 activation in cardiomyocytes regulated the transcription of tissue remodeling genes.
Ang II-Induced STAT3 Activation and IL-6 Production Are Prevented in TLR4 −/− Mice
We next investigated the roles of Ang II-mediated STAT3 activation and TLR4 in vivo using Ang II infusion in WT or TLR4 −/− mice ( Figure S5A ) treated with S3i-201. The Ang II infusion increased Ang II protein levels in the heart of WT mice ( Figure 5A ), which was likely attributed to Ang II sequestration from the circulation. 29 It is possible, however, that Ang II administration may also increase local production. Figure S5B ). In addition, real-time quantitative polymerse chain reaction assay showed that Ang II infusion resulted in a feedback decrease in ACE expression in mouse hearts, which was also unaffected by TLR4 −/− or S3i-201 ( Figure S5C ). Ang II infusion increased protein levels of TLR4 protein in WT mice ( Figure S5D ), but STAT3 inhibition did not significantly change this expression. These studies point to a potential role of TLR4 in Ang II-induced responses in vivo and justify the use of TLR4 −/− mice to tease out the signaling mechanisms.
All groups showed no significant changes in mouse body weight ( Figure S5E ). Ang II significantly increased the SBP in both WT and TLR4 −/− mice, while neither S3i-201 nor TLR4
−/− influenced SBP ( Figure 5B ). This is consistent with our previous finding that blockade of the TLR4 co-receptor MD2 did not affect Ang II-induced hypertension. 3 We, therefore, determined the STAT3 phosphorylation status in heart tissue in mice and found that Ang II administration increased p-STAT3 levels ( Figure 5C ), which was inhibited by the STAT3 inhibitor, S3i-201. Interestingly, the Ang II-induced increased p-STAT3 was not seen in TLR4 knockout mice. These results are consistent with our in vitro observations implicating TLR4 in STAT3 activation in cardiomyocytes. Because we found that the TLR4-mediated STAT3 activation in response to Ang II increased IL-6 production in cardiomyocytes, we also assessed IL-6 levels in mouse myocardial tissues and serum. Results indicated that in Figure 5D and 5E, the myocardial tissue and serum content of IL-6 in Ang II-administered mice remained at control levels with S3i-201 treatment or TLR4 knockout. Together, these results show that Ang II upregulated IL-6 through TLR4-dependent STAT3 activation.
STAT3 Inhibition Reduces Ang II-Induced Cardiac Fibrosis and Hypertrophy
We first determined the protective effects of STAT3 inhibitor, S3i-201, on Ang II-induced cardiac function assessed by transthoracic echocardiography. We found that Ang IIinduced depression of ejection fraction, fractional shortening, and other cardiac functional deficits were prevented in mice treated with S3i-201 ( Figure 5F ; Table S1 ). As expected, Ang II administration of TLR4 −/− mice also showed control ejection fraction, fractional shortening, and other cardiac functional parameters ( Figure 5F ; Table S1 ).
The findings from the mouse cardiac function studies suggested that STAT3 inhibition and TLR4 deficiency likely would also prevent Ang II-induced myocardial remodeling. We observed that Ang II increased myocardial fibrosis and collagen deposition as evaluated by Masson's Trichome and Sirius Red, respectively, but this fibrotic response was prevented in WT mice treated with S3i-201 and in TLR4 −/− mice ( Figure 6A ; Figure S6A and S6B).
Histological evaluation of hematoxylin and eosin-stained mouse myocardial tissue indicated that increased myofiber cross-sectional area ( Figure 6A ) and disorganized myofibers occurred in WT Ang II-treated mice ( Figure S6C ) but not in TLR4 −/− mice or in WT mice treated with S3i-201.
Measurement of heart weight normalized to body weight ratios ( Figure 6B ) or heart weight normalized to tibia length ( Figure S6D ) and cardiomyocyte cell size ( Figure 6A ) were consistent with these results, indicating that STAT3 inhibition prevented cardiac hypertrophy. Significantly, the protective effects of STAT3 inhibition or TLR4 deficiency in Ang II-induced hypertrophic and fibrotic responses in the mouse models were accompanied by inhibition of Ang II-induced increased mRNA expression of the hypertrophy marker, MyHC ( Figure 6C) , and fibrogenic genes, Col-1 and TGF-β ( Figure 6D and 6E) . Collectively, these results showed that mice with STAT3 inhibition or TLR4 deficiency were resistant to Ang II-induced cardiac hypertrophy and fibrosis.
Discussion
The key findings of our study indicated that Ang II stimulated direct association between TLR4 and STAT3 in an early phase of STAT3 activation, resulting in increased IL-6 production, which induced the second STAT3 activation. Inhibition of STAT3 or deficiency of TLR4 attenuated Ang II-induced cardiac remodeling in vivo, resulting in preservation of cardiac function. We conclude that Ang II-induced cardiac remodeling depends, at least in part, on STAT3 activation through TLR4 (working model shown in Figure 6F ). The myocardial tissue injury, inflammation, and hypertension observed in the Ang II-induced mice of the current study are consistent with our previous findings. 3, 30, 31 We designed an acute mouse model based on a single subcutaneous injection of Ang II (1.0 mg/kg) or a subacute model using subcutaneous injections of 0.5 mg/kg every 2 days. 3, 30, 31 Although delivery of Ang II using a subcutaneously implanted osmotic mini pump is another approach, providing a chronic model for study, we have not included this for comparison. It should be noted that work by González et al 32 have used the mini pump for chronic delivery of Ang II in mice and reported a similar heart injury profile characterized by myocardial fibrosis, macrophage infiltration, increased production of pro-inflammatory cytokines, and cardiac dysfunction, indicating that the chronically administered Ang II yielded a similar myocardial injury profile as our acute/subacute mouse model.
Our finding that Ang II-mediated cardiac remodeling and phosphorylation of STAT3 were markedly alleviated in TLR4 −/− mice indicated that Ang II-activated STAT3 required TLR4. Moreover, the Ang II-induced STAT3 activation in H9C2 cells was biphasic and TLR4-dependent. The early STAT3 activation involved STAT3 complex formation with TLR4, which was followed by tyrosine phosphorylation in a MyD88-and JAK2-independent mechanism, peaking around 1 hour post Ang II exposure. In the late activation phase, STAT3 phosphorylation was dependent on the classic IL-6 and gp130 pathway, peaking 12 hours post-Ang II exposure. These latter observations provided evidence that the late STAT3 activation was likely through IL-6 functioning as the paracrine factor. For these in vitro culture studies, the cardiomyocytes were stimulated with 1 µmol/L of Ang II, a dose based on preliminary dose-response studies. One likely reason for this relatively high concentration was attributed to cardiomyocytes not signaling directly through its cognate angiotensin receptors, a finding consistent with the report by Watkins et al. 18 Additionally, we recently reported that Ang II activates the MD2-TLR4 immune signaling complex in cardiomyocytes through direct binding to MD2 in signaling pro-indlammatory activities. 3 Our studies have identified TLR4 as one mechanism by which Ang II activated STAT3 in myocardial remodeling. The role of TLR4 in the pathogenesis of Ang II-induced cardiac remodeling is supported by several studies. Using TLR4-deficient mice, Matsuda et al 33 demonstrated that TLR4 deficiency reversed Ang II-induced cardiac hypertrophy, monocyte/ macrophage infiltration, and diastolic dysfunction, regardless of changes in blood pressure. Ang II also increases TLR4 expression in vascular cells 34 and TLR4 inhibition reduces Ang II-induced inflammatory phenotype. 35 Consistently, we demonstrated that Ang II upregulated myocardial TLR4 expression of mice, and TLR4 knockout significantly attenuated Ang II-induced STAT3 phosphorylation, cardiac dysfunction, and myocardial remodeling independent of altering SBP. The finding that Ang II-mediated STAT3 phosphorylation is markedly reduced in ApoE −/− TLR4 −/− mice and in ApoE −/− mice treated with TLR4 inhibitor Eritoran further supports TLR4 involvement in Ang II-induced STAT3 activation. 17 We identified a novel mechanism in which STAT3 inhibition protected against Ang II-induced cardiac dysfunction. However, it is not clear whether the protective effects of STAT3 inhibition were limited to Ang II challenge. STAT3 plays different roles in different heart diseases. STAT3 activation mediates cardioprotection against ischemia/reperfusion 36 and doxorubicin 37 induction. This is because that cardiac cell apoptosis is a main pathological process in these injuries, and STAT3 activation promotes cell proliferation, countering apoptosis. However, STAT3 appears to play a pathological role in Ang II-induced heart injuries, 38 as shown by the protective effect of the small-molecule STAT3 inhibitor, 9 which is likely related to the fact that STAT3-mediated hypertrophy and fibrosis are main pathological processes in Ang II-induced injuries. In addition, different STAT3 inhibition methods may lead to different outcomes in Ang II-induced cardiac injuries. Global STAT3 gene knockout aggravates Ang II-induced heart injuries, 10 whereas cardiac-specific STAT3 knockout increases susceptibility to cardiac injury in mice. 39 This may be because of the importance of STAT3 in heart development and cardiomyogenesis. 40 Therefore, both global STAT3 knockout and cardiomyocyte-specific STAT3 knockout affects cardiac development and function, which may further aggravate cardiac injury in pathological models. It would be important to study inducible cardiomyocyte-specific STAT3 knockout only during specific stresses to rule out developmental changes.
Findings from the cell culture studies further supported a pathological role of STAT3 in Ang II-induced heart injury. STAT3 inhibition with S3i-201, selective for the Src homology 2 domain of STAT3, prevented Ang II-induced hypertrophy and fibrosis in H9C2 cells and primary cardiomyocytes. The pharmacological inhibition of STAT3 is advantageous and paves the way to establish the importance of STAT3 as a therapeutic target in Ang II-induced cardiac remodeling. Here, we showed that S3i-201 significantly attenuated Ang II-induced cardiac remodeling and dysfunction, independent of the SBP level. These findings indicated that S3i-201 may be an excellent candidate or parent compound for further drug development.
Perspectives
We showed that Ang II initiated an early activation of STAT3 in cardiomyocytes requiring TLR4, but not IL-6/gp130/JAK2, resulting in IL-6 expression. The IL-6 induced the second activation of STAT3, which upregulated expression of matrix proteins and cardiomyocyte remodeling genes. The inhibition of STAT3 or TLR4 in Ang II-challenged cardiomyocytes or moue models prevented cardiomyocyte hypertrophy and myocardial fibrosis, which preserved normal cardiac function. Furthermore, these cardioprotective effects of STAT3 and TLR4 inhibition occurred without changes to blood pressure. Overall, we report a novel mechanism by which Ang IIinduced cardiac dysfunction and remodeling were regulated December 2018 by activated STAT3. The findings also support STAT3 as a potential therapeutic target in the treatment of ventricular remodeling.
